|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar
|
|
2
|
Dubecz A, Kohler J and Stein HJ:
Cholecystectomy in a trial of adjuvant chemotherapy after
pancreatic cancer resection. JAMA. 304:2590author reply 2590–2591.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torpy JM, Burke AE and Glass RM: JAMA
patient page. Pancreatic cancer. JAMA. 304:11402010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gu WJ and Liu HL: Induction of pancreatic
cancer cell apoptosis, invasion, migration, and enhancement of
chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by
hnRNP A2/B1 siRNA. Anticancer Drugs. 24:566–576. 2013.PubMed/NCBI
|
|
6
|
Bhattacharyya M, Francis J, Eddouadi A,
Lemoine NR and Hallden G: An oncolytic adenovirus defective in
pRb-binding (dl922–947) can efficiently eliminate pancreatic cancer
cells and tumors in vivo in combination with 5-FU or gemcitabine.
Cancer Gene Ther. 18:734–743. 2011.
|
|
7
|
Oberic L, Viret F, Baey C, Ychou M,
Bennouna J, Adenis A, Peiffert D, Mornex F, Pignon JP, Celier P,
Berille J and Ducreux M: Docetaxel- and 5-FU-concurrent
radiotherapy in patients presenting unresectable locally advanced
pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial’s
pre-planned analysis and case report of a 5.5-year disease-free
survival. Radiat Oncol. 6:1242011.PubMed/NCBI
|
|
8
|
Ischenko I, Seeliger H, Jauch KW and Bruns
CJ: Metastatic activity and chemotherapy resistance in human
pancreatic cancer - influence of cancer stem cells. Surgery.
146:430–434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang C, Kolb A, Buchler P, Cato AC,
Mattern J, Rittgen W, Edler L, Debatin KM, Buchler MW, Friess H and
Herr I: Corticosteroid co-treatment induces resistance to
chemotherapy in surgical resections, xenografts and established
cell lines of pancreatic cancer. BMC Cancer. 6:612006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu QH, Zhang J, Zhao CY, Yu DH, Bu HJ,
Chen Y, Ni CY and Zhu MH: Surviving cells after treatment with
gemcitabine or 5-fluorouracil for the study of de novo resistance
of pancreatic cancer. Cancer Lett. 314:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsujie M, Nakamori S, Nakahira S,
Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K,
Sakon M and Monden M: Human equilibrative nucleoside transporter 1,
as a predictor of 5-fluorouracil resistance in human pancreatic
cancer. Anticancer Res. 27:2241–2249. 2007.PubMed/NCBI
|
|
12
|
Shi X, Liu S, Kleeff J, Friess H and
Buchler MW: Acquired resistance of pancreatic cancer cells towards
5-fluorouracil and gemcitabine is associated with altered
expression of apoptosis-regulating genes. Oncology. 62:354–362.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coleman MC, Asbury CR, Daniels D, Du J,
Aykin-Burns N, Smith BJ, Li L, Spitz DR and Cullen JJ:
2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and
radiosensitization in pancreatic cancer. Free Radic Biol Med.
44:322–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nam SO, Yotsumoto F, Miyata K, Shirasu N,
Miyamoto S and Kuroki M: Possible therapeutic targets among the
molecules involved in the Warburg effect in tumor cells. Anticancer
Res. 33:2855–2860. 2013.PubMed/NCBI
|
|
15
|
Dang CV: Rethinking the Warburg effect
with Myc micromanaging glutamine metabolism. Cancer Res.
70:859–862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JW and Dang CV: Cancer’s molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930.
2006.
|
|
17
|
Samudio I, Fiegl M and Andreeff M:
Mitochondrial uncoupling and the Warburg effect: molecular basis
for the reprogramming of cancer cell metabolism. Cancer Res.
69:2163–2166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samudio I, Fiegl M, McQueen T, Clise-Dwyer
K and Andreeff M: The Warburg effect in leukemia-stroma cocultures
is mediated by mitochondrial uncoupling associated with uncoupling
protein 2 activation. Cancer Res. 68:5198–5205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu D, Zhang Y, Dang C, Ma Q, Lee W and
Chen W: siRNA directed against TrkA sensitizes human pancreatic
cancer cells to apoptosis induced by gemcitabine through an
inactivation of PI3K/Akt-dependent pathway. Oncol Rep. 18:673–677.
2007.PubMed/NCBI
|
|
20
|
Robey RB and Hay N: Is Akt the ‘Warburg
kinase’?-Akt-energy metabolism interactions and oncogenesis. Semin
Cancer Biol. 19:25–31. 2009.
|
|
21
|
Aft RL, Zhang FW and Gius D: Evaluation of
2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell
death. Br J Cancer. 87:805–812. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pelicano H, Martin DS, Xu RH and Huang P:
Glycolysis inhibition for anticancer treatment. Oncogene.
25:4633–4646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ben Sahra I, Laurent K, Giuliano S,
Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y,
Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger
P, Tanti JF and Bost F: Targeting cancer cell metabolism: the
combination of metformin and 2-deoxyglucose induces p53-dependent
apoptosis in prostate cancer cells. Cancer Res. 70:2465–2475.
2010.
|
|
24
|
Kurtoglu M, Gao N, Shang J, Maher JC,
Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN and Lampidis TJ:
Under normoxia, 2-deoxy-D-glucose elicits cell death in select
tumor types not by inhibition of glycolysis but by interfering with
N-linked glycosylation. Mol Cancer Ther. 6:3049–3058. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aft RL, Lewis JS, Zhang F, Kim J and Welch
MJ: Enhancing targeted radiotherapy by copper(II)diacetyl-
bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer
Res. 63:5496–5504. 2003.PubMed/NCBI
|
|
26
|
Maschek G, Savaraj N, Priebe W,
Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR and Lampidis
TJ: 2-deoxy-D-glucose increases the efficacy of adriamycin and
paclitaxel in human osteosarcoma and non-small cell lung cancers in
vivo. Cancer Res. 64:31–34. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Wang Z, Chang P, Xiang L, Pan F,
Li J, Jiang J, Zou L, Yang L, Bian Z and Liang H: The effect of
focal adhesion kinase gene silencing on 5-fluorouracil
chemosensitivity involves an Akt/NF-kappaB signaling pathway in
colorectal carcinomas. Int J Cancer. 127:195–206. 2010. View Article : Google Scholar
|
|
28
|
You F, Aoki K, Ito Y and Nakashima S: AKT
plays a pivotal role in the acquisition of resistance to
5-fluorouracil in human squamous carcinoma cells. Mol Med Rep.
2:609–613. 2009.PubMed/NCBI
|
|
29
|
Upadhyay AK, Singh S, Chhipa RR,
Vijayakumar MV, Ajay AK and Bhat MK: Methyl-beta-cyclodextrin
enhances the susceptibility of human breast cancer cells to
carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and
Bcl-2. Toxicol Appl Pharmacol. 216:177–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kodach LL, Bos CL, Duran N, Peppelenbosch
MP, Ferreira CV and Hardwick JC: Violacein synergistically
increases 5-fluorouracil cytotoxicity, induces apoptosis and
inhibits Akt-mediated signal transduction in human colorectal
cancer cells. Carcinogenesis. 27:508–516. 2006. View Article : Google Scholar
|
|
31
|
Yang H, Ni L, Ma YQ and Song YG: PI3K
p85alpha gene silencing by RNA interference promotes
5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells.
Nan Fang Yi Ke Da Xue Xue Bao. 30:1085–1088. 2010.(In Chinese).
|
|
32
|
Cheng Y, Diao DM, Zhang H, Song YC and
Dang CX: Proliferation enhanced by NGF-NTRK1 signaling makes
pancreatic cancer cells more sensitive to 2DG-induced apoptosis.
Int J Med Sci. 10:634–640. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blouin MJ, Zhao Y, Zakikhani M, Algire C,
Piura E and Pollak M: Loss of function of PTEN alters the
relationship between glucose concentration and cell proliferation,
increases glycolysis, and sensitizes cells to 2-deoxyglucose.
Cancer Lett. 289:246–253. 2010. View Article : Google Scholar
|
|
34
|
Mizuno S, Nakai Y, Isayama H, Takahara N,
Miyabayashi K, Yamamoto K, Kawakubo K, Mohri D, Kogure H, Sasaki T,
Yamamoto N, Sasahira N, Hirano K, Tsujino T, Ijichi H, Tateishi K,
Tada M and Koike K: Diabetes is a useful diagnostic clue to improve
the prognosis of pancreatic cancer. Pancreatology. 13:285–289.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McAuliffe JC and Christein JD: Type 2
diabetes mellitus and pancreatic cancer. Surg Clin North Am.
93:619–627. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aggarwal G, Kamada P and Chari ST:
Prevalence of diabetes mellitus in pancreatic cancer compared to
common cancers. Pancreas. 42:198–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mizuno S, Nakai Y, Isayama H, Yanai A,
Takahara N, Miyabayashi K, Yamamoto K, Kawakubo K, Mohri D, Kogure
H, Sasaki T, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Ijichi H,
Tateishi K, Akanuma M, Tada M and Koike K: Risk factors and early
signs of pancreatic cancer in diabetes: screening strategy based on
diabetes onset age. J Gastroenterol. 48:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Florena AM, Tripodo C, Guarnotta C, Ingrao
S, Porcasi R, Martorana A, Lo Bosco G, Cabibi D and Franco V:
Associations between Notch-2, Akt-1 and HER2/neu expression in
invasive human breast cancer: a tissue microarray immunophenotypic
analysis on 98 patients. Pathobiology. 74:317–322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cen B, Mahajan S, Wang W and Kraft AS:
Elevation of receptor tyrosine kinases by small molecule akt
inhibitors in prostate cancer is mediated by Pim-1. Cancer Res.
73:3402–3411. 2013. View Article : Google Scholar
|
|
40
|
Floc’h N, Kinkade CW, Kobayashi T, Aytes
A, Lefebvre C, Mitrofanova A, Cardiff RD, Califano A, Shen MM and
Abate-Shen C: Dual targeting of the Akt/mTOR signaling pathway
inhibits castration-resistant prostate cancer in a genetically
engineered mouse model. Cancer Res. 72:4483–4493. 2012.PubMed/NCBI
|
|
41
|
Dansen TB and Burgering BM: Unravelling
the tumor-suppressive functions of FOXO proteins. Trends Cell Biol.
18:421–429. 2008. View Article : Google Scholar : PubMed/NCBI
|
